Immunotherapy

The U.S. Food and Drug Administration (FDA) has recently expanded the use of Keytruda (pembrolizumab), an immunotherapy drug, marking a significant advancement in the treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). Approved on September 17, 2024, the combination of Keytruda with pemetrexed and platinum-based chemotherapy offers new hope to mesothelioma patients, who…